R
Robert Lemos
Researcher at University of Texas MD Anderson Cancer Center
Publications - 21
Citations - 1653
Robert Lemos is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Cancer cell & Protein kinase B. The author has an hindex of 15, co-authored 21 publications receiving 1451 citations. Previous affiliations of Robert Lemos include Discovery Institute & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
The Hypoxia-Associated Factor Switches Cells from HIF-1α– to HIF-2α–Dependent Signaling Promoting Stem Cell Characteristics, Aggressive Tumor Growth and Invasion
TL;DR: HAF, by causing a switch from a HIF-1α- to Hif-2α-dependent response to hypoxia, provides a mechanism for more aggressive growth of tumors under prolongedhypoxia.
Journal ArticleDOI
Mutations in the Phosphatidylinositol-3-Kinase Pathway Predict for Antitumor Activity of the Inhibitor PX-866 whereas Oncogenic Ras Is a Dominant Predictor for Resistance
Nathan T. Ihle,Robert Lemos,Peter Wipf,Adly Yacoub,Clint Mitchell,Doris R. Siwak,Gordon B. Mills,Paul Dent,D. Lynn Kirkpatrick,Garth Powis +9 more
TL;DR: Studies using an H-Ras construct to constitutively and preferentially activate the three best-defined downstream targets of Ras showed that mutant Ras mediates resistance through its ability to use multiple pathways for tumorigenesis.
Journal ArticleDOI
Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents
Muling Mao,Feng Tian,John M. Mariadason,Chun C. Tsao,Robert Lemos,Farshid Dayyani,Y.N. Vashisht Gopal,Zhi-Qin Jiang,Ignacio I. Wistuba,Xi M. Tang,William G. Bornman,Gideon Bollag,Gordon B. Mills,Garth Powis,Jayesh Desai,Gary E. Gallick,Michael A. Davies,Scott Kopetz +17 more
TL;DR: It is shown that activation of the PI3K/AKT pathway is a mechanism of both innate and acquired resistance to BRAF inhibitors in BRAFV600E CRC and suggest combinatorial approaches to improve outcomes in this poor prognosis subset of patients.
Journal ArticleDOI
The Promise of Patient-Derived Xenografts: The Best Laid Plans of Mice and Men
TL;DR: Compared with xenografts from previously established cell lines, patient-derived xenografteds may more faithfully recapitulate the molecular diversity, cellular heterogeneity, and histology seen in patient tumors, although other limitations of murine models remain.
Journal ArticleDOI
In vivo therapeutic silencing of hypoxia-inducible factor 1 alpha (HIF-1α) using single-walled carbon nanotubes noncovalently coated with siRNA
Geoffrey Bartholomeusz,Paul Cherukuri,Paul Cherukuri,John Kingston,Laurent Cognet,Laurent Cognet,Robert Lemos,Tonya K. Leeuw,Laura Gumbiner-Russo,R. Bruce Weisman,Garth Powis +10 more
TL;DR: When complexes containing siRNA targeted to hypoxia-inducible factor 1 alpha (HIF-1α) were added to cells growing in serum containing culture media, there was strong specific inhibition of cellular Hif-1 activity.